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ﬁ nancial reasons). Biological licenses and tentative approvals were excluded from 
analysis. Results were obtained using descriptive statistics and chi-squared tests. 
RESULTS: FDA databases contained a total of 2093 drug product and combination 
approvals between February 1939 and December 2008. Of those products, 42.3% 
had generic competition. A total of 595 (28.4%) drug products were discontinued
during the study period. Discontinued products included 37.2% of the brand products 
and 15.6% of the generic products (p  0.001). Safety was the reason for discontinu-
ation for 59 drug products, which represented 2.8% of the approved drugs and 
accounted for 9.9 % of the product discontinuations. Databases contained 23,931
approvals, including 8,174 NDAs and 15,757 ANDAs. Discontinued applications
accounted for 42.3% of all applications, and included 43.9% of the NDAs and 41.8% 
of the ANDAs approved during the study period. CONCLUSIONS: One-third of the
drugs approved by the FDA and more than 40% of the applications were discontinued 
during the study period. Safety discontinuations constituted a small, but signiﬁ cant, 
percentage of the discontinuations. Other reasons for discontinuation included
product obsolescence and ﬁ nancial reasons. Drug discontinuations pose signiﬁ cant 
implications for research, product development, and determining societal needs for
innovative pharmaceutical products.
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CONTENT ANALYSIS OF OFF-LABEL DRUG USE: REPORTING PRINT
MEDIA COVERAGE
Patel DA
Virginia Commonwealth University, Richmond, VA, USA
OBJECTIVES: To assess newspaper coverage of ‘off-label drug and medical device
use’ over the period of 1990 to 2008, explore key themes of discussion, and identify
the tone of coverage. METHODS: The ProQuest media database was accessed for 
news articles published from January 1990 to July 2008 from the top six selling 
national newspapers. From the initial 1066 articles retrieved, 153 were selected for 
analysis based on inclusion and exclusion criteria. Main outcome measures were the 
number of articles published; type of themes covered; headline, content and overall
article tone (positive, negative or neutral); speciﬁ c concerns and beneﬁ ts discussed 
with off-label use; and primary individual interviewed for the article. RESULTS:
The articles published on off-label drug use steadily increased over the period of 
study. The primary themes discussed were concerns over safety and efﬁ cacy (44.4%), 
beneﬁ ts of off-label prescribing (26.8%), general announcements by the FDA (9.2%), 
insurance coverage issues (6.5%), and combination of beneﬁ ts and concerns (12.4%).
The tone of headlines was mainly neutral (60.1%) although one quarter was negative 
(25.5%). Within the articles, however, the overall tone was judged more negative for
off-label use (39.9% of articles). The majority of articles (58.8%) used clinicians as 
the primary commenter with other articles using government representatives (11.1%)
patients and patient advocates (7.8%), and drug company spokespeople (5.9%) 
for comments. Inter-coder reliability were in the acceptable ranges, Cohen’s kappa 
(0.7–0.85) and percentage agreement (80%). CONCLUSIONS: Off-label drug use
has gotten increasing media attention over the years. An understanding of the media 
coverage enables us to get a better understanding of public perception on this issue.
Overall, coverage has been more negative than positive with articles expressing more 
concerns than beneﬁ ts. Moreover, off-label prescribing is an important and a sensitive 
issue and hence, media sources should be urged to present this topic with a neutral
approach.
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WASTED MEDICATION: HOW BIG IS THE PROBLEM?
Ryvkin M, Garavaglia S
Medco Health Solutions, Inc., Franklin Lakes, NJ, USA
OBJECTIVES: To quantify medication wastage for Lipid Lowering Agents, Antihy-
pertensive Therapy, and Proton Pump Inhibitors. METHODS: This study focused on 
drug waste for new to therapy patients. The therapy classes under consideration were 
Lipid Lowering Agents (N  12,978), Antihypertensive Therapy (N  15,975), and
Proton Pump Inhibitors (N  14,365). The claims came from an aggregate of a segment
of Medco Health Solutions clients. We calculated overall percentage of patients that 
wasted medication as well as percentage of days supply that they wasted. To focus on
avoidable waste, we deﬁ ned a wastage event as a switch within therapeutic class. We 
also stratiﬁ ed the days supply into 3 categories less than or equal to 30 days, between 
30 and 90 days, and greater than or equal to 90 days. RESULTS: For Lipid Lowering
Therapy: Overall 1.5% of patients had wastage of 0.7% days supplied. Stratiﬁ cation
by days: days   30 1.2% of patients and 0.4% of days, 30  days 90 2.4% of 
patients and 0.9% of days, days   90 2.9% patients and 1.2% of days. For Anti-
hypertensive Therapy: 6.2% patients had wastage of 2% days supplied. Stratiﬁ cation
by days: days   30 6.3% of patients and 2.1% of days, 30  days 90 5.1% of 
patients and 2.1% of days, days   90 5.2% patients and 2% of days. For PPI’s: 
1.9% patients had wastage of 0.7% days supplied. Stratiﬁ cation by days: days   30 
1.9% patients and 0.7% of days, 30  days 90 0.9% of patients and 0.3% of days, 
days   90 1.8% patients and 0.7% of days. CONCLUSIONS: The drug wastage 
for the above therapies is very small and so is the difference between the wastage for
30 day supply vs. 90 or greater day supply. Therefore drug wastage should not be a 
major concern when choosing different plan designs.
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OBJECTIVES: To analyze medication costs and utilization in hospice care using PBM 
claims data from hospices in Ohio. METHODS: A retrospective analysis was con-
ducted using claims from January 1 through December 31 2007 from ﬁ ve hospices in
Ohio. The data contains information regarding prescription medication utilization and 
their costs. Descriptive analyses were conducted to identify ten therapeutic drug classes 
with the most frequent utilization rates and largest percentage of expenditures. 
Further, descriptive analyses were conducted to examine the differences in prescription
drug count and total cost by therapeutic class and by drug name for each hospice and
for all hospices combined. RESULTS: The average number of admissions in each 
hospice for the calendar year 2007 was 527, 50.6% being male. The drug expenditures 
for each hospice averaged $498,301 per year. Approximately 1020 different medica-
tions under 246 therapeutic classes were found to be utilized in the ﬁ ve hospices. The 
most frequently utilized therapeutic class of medications, based on prescription medi-
cation count included analgesic-narcotics (14.9%) followed by laxatives-cathartics
(7.2%), and anti-anxiety drugs (6.7%). Therapeutic classes contributing to the major-
ity of drug expenditures included opioid analgesics (16.5%), SSRIs (4.7%), and anti-
anxiety drugs (4.5%). Medications whose frequency of use contribute to signiﬁ cant
expense include morphine sulfate (5.3% – utilization & 4.4% – expenses), and loraz-
epam (4.4% & 3.1%.). Individual drug products not frequently utilized, although
signiﬁ cantly contribute to expenses include fentanyl (3.5%) and low molecular weight 
heparin products(3.1%). CONCLUSIONS: Although the overall costs for hospice care 
to Medicare and patients is less as compared to the costs incurred by conventional 
non-palliative focused care, the cost for medications in a hospice program is signiﬁ -
cant. Hospices should place emphasis on the utilization of cost effective drugs that
can be used among terminally ill patients to provide a high level of quality care with
ﬁ scal responsibility.
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OBJECTIVES: We characterized a sub-population of Premera BlueCross members on 
multiple chronic medications and evaluated an educational, mail-based program 
designed to address the safety of multiple prescription users. METHODS: Polyphar-
macy members were selected based on early 2005 chronic prescription claims. Selected
members were   19 years of age and were continuously eligible for both prescription
and medical beneﬁ ts during the evaluation period (August 2004–January 2007).
Pharmacy and medical claims were analyzed to compare monthly medication frequen-
cies and safety-related medical events (emergency room (ER) visits and hospitaliza-
tions) between the pre- and post-intervention periods. Generalized linear mixed 
modeling was used to test for time-period differences in prescriptions. The top ICD-9 
codes for ER visits and hospitalizations, as well as the most frequently prescribed 
medications were reported. Polypharmacy members were grouped into medication-
count categories and prescription and medical event proﬁ les were developed.
RESULTS: For the ﬁ nal analysis sample of N  12,962 members (65% female; mean
age: 53 years), a comparison of the two periods indicated an increase of approximately 
0.5 in mean monthly medication counts during the post-period (6.3 vs. 6.8 prescrip-
tions; p  0.0001). GLMM applied to monthly medications indicated signiﬁ cant dif-
ferences in the mean number of monthly medications at period start as well as in the
slope of monthly medication trends during the periods. ER visits and hospitalizations 
(safety-related events) were reduced by roughly 1% in the post-period (23% to 22%, 
13% to 12%, respectively; both p  0.0001). Reductions in events were observed 
across medication-count categories. Medications for hypertension, high LDL choles-
terol, and diabetes were among the most frequently prescribed in both periods. 
CONCLUSIONS: This evaluation demonstrates the need for more studies and focus 
on sub-populations of health challenged members. Well-designed, controlled studies
could further test the effects of medical/pharmacist intervention strategies for members
taking multiple medications.
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PRESCRIBING IN ELDERLY OUTPATIENTS: A COHORT STUDY
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OBJECTIVES: To establish explicit criteria for potentially inappropriate medication 
prescribing (PIP) for the elderly and assess the prevalence of and factors associated 
with PIP among elderly residents in the Local Health Unit (LHU) of Parma, Italy 
according to the developed criteria. METHODS: A nine-member expert panel was 
convened to develop a list of inappropriate medications reﬂ ecting the Italian pres-
cribing habits. Using the 2002 Beers criteria as a framework, consensus through a 
two-round Delphi method was reached to classify the identiﬁ ed 23 inappropriate 
medications into three categories: 17 medications to be always avoided, 3 medications 
rarely appropriate, and 3 medications with some indications but often misused. A 
retrospective cohort study using the 2006 Parma LHU automated outpatient prescrip-
tions database was conducted. The cohort comprised 91,741 individuals q65 years 
